BOLD Key Statistics, Chart & Performance
The current stock price of BOLD is 1.26 USD. In the past month the price increased by 4.13%. In the past year, price decreased by -47.72%.
BOLD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BOLD. When comparing the yearly performance of all stocks, BOLD is a bad performer in the overall market: 89.65% of all stocks are doing better.
BOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLD. No worries on liquidiy or solvency for BOLD as it has an excellent financial health rating, but there are worries on the profitability.
BOLD Financial Highlights
Over the last trailing twelve months BOLD reported a non-GAAP Earnings per Share(EPS) of -2.77. The EPS decreased by -484.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.6% | ||
| ROE | -56.06% | ||
| Debt/Equity | 0 |
BOLD Forecast & Estimates
7 analysts have analysed BOLD and the average price target is 3.06 USD. This implies a price increase of 142.86% is expected in the next year compared to the current price of 1.26.
BOLD Ownership
About BOLD
Company Profile
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Company Info
BOUNDLESS BIO INC
10955 Alexandria Way, Suite 100
San Diego CALIFORNIA 94108 US
CEO: Matthew R. Patterson
Employees: 64
Phone: 18587669912
BOUNDLESS BIO INC / BOLD FAQ
What does BOLD do?
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
What is the stock price of BOUNDLESS BIO INC today?
The current stock price of BOLD is 1.26 USD. The price decreased by -0.79% in the last trading session.
What is the dividend status of BOUNDLESS BIO INC?
BOLD does not pay a dividend.
How is the ChartMill rating for BOUNDLESS BIO INC?
BOLD has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of BOLD stock?
BOUNDLESS BIO INC (BOLD) operates in the Health Care sector and the Biotechnology industry.
How many employees does BOUNDLESS BIO INC have?
BOUNDLESS BIO INC (BOLD) currently has 64 employees.
Who owns BOUNDLESS BIO INC?
You can find the ownership structure of BOUNDLESS BIO INC (BOLD) on the Ownership tab.